PHOENIXVILLE, Pennsylvania.--(BUSINESS WIRE)—Affinity BioCeuticals, LLC, CEO, Christina DiArcangelo Puller announced that she has added a Chief Medical Officer, William E. Gannon, Jr., M.D., M.B.A., to Affinity BioCeuticals. LLC.  Dr. Gannon, has served as Chief Scientific Officer and Medical Director for Capital City Technical Consulting in Washington, DC. In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion. Dr. Gannon has held positions in multinational CRO’s, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., Dr. Gannon served as Vice President – Clinical & Medical Affairs in biotechnology arena. Dr. Gannon’s expertise has a focus in oncology, but possesses a board range of experience across therapeutic, device and biologic categories. Dr. Gannon has managed clinical trials and operations as well as the design, corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia. 

In his role as Chief Medical Officer, Dr. Gannon will lead Affinity BioCeuticals with the strategy, direction and execution of the Affinity BioCeuticals Clinical Development Plans which will meet the strategic directives for the organization. Dr. Gannon will also work very closely with the Affinity BioCeuticals, CEO, Christina DiArcangelo Puller and the rest of the Executive team.

"We are honored to announce the hiring of Dr. Gannon, who I know will bring his focus and passion for excellence in patient care and clinical development innovation to Affinity BioCeuticals.  Dr. Gannon is an intensely disciplined, medical professional who demands the best in quality and safety as well as ensuring that we focus on unmet therapeutic needs for the patients who will benefit by Medical Cannabis.  Dr. Gannon’s astute understanding of global clinical trials as well as the ability to design and implement regulatory strategies and submissions will be invaluable to Affinity BioCeuticals." said Christina DiArcangelo Puller, CEO, Affinity BioCeuticals.

About Affinity BioCeuticals

Affinity BioCeuticals is the First Pennsylvania's Pioneer Biotech organization spearheading the advancement of Medical Cannabis as a viable medical treatment option.  Affinity BioCeuticals initially intends to focus its efforts on the targets mentioned below:

  • Opioid Abuse
  • PTSD
  • Anxiety
  • Oncology Supportive Care

For more information on the company or general inquiries, please email: or visit us at

Forward Looking Statements

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,” ”predictable,” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.